JP6622299B2 - テトラヒドロイソキノリン誘導体 - Google Patents
テトラヒドロイソキノリン誘導体 Download PDFInfo
- Publication number
- JP6622299B2 JP6622299B2 JP2017518989A JP2017518989A JP6622299B2 JP 6622299 B2 JP6622299 B2 JP 6622299B2 JP 2017518989 A JP2017518989 A JP 2017518989A JP 2017518989 A JP2017518989 A JP 2017518989A JP 6622299 B2 JP6622299 B2 JP 6622299B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dichlorophenyl
- dihydroisoquinolin
- ethanone
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188174 | 2014-10-08 | ||
| EP14188174.8 | 2014-10-08 | ||
| PCT/EP2015/073053 WO2016055479A1 (en) | 2014-10-08 | 2015-10-06 | Tetrahydroisoquinoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530185A JP2017530185A (ja) | 2017-10-12 |
| JP2017530185A5 JP2017530185A5 (show.php) | 2019-10-03 |
| JP6622299B2 true JP6622299B2 (ja) | 2019-12-18 |
Family
ID=51790569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518989A Active JP6622299B2 (ja) | 2014-10-08 | 2015-10-06 | テトラヒドロイソキノリン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10105359B2 (show.php) |
| EP (1) | EP3204359B1 (show.php) |
| JP (1) | JP6622299B2 (show.php) |
| CN (1) | CN107001278B (show.php) |
| BR (1) | BR112017007123B1 (show.php) |
| CA (1) | CA2963951C (show.php) |
| CY (1) | CY1123417T1 (show.php) |
| DK (1) | DK3204359T3 (show.php) |
| EA (1) | EA035544B1 (show.php) |
| ES (1) | ES2821821T3 (show.php) |
| HR (1) | HRP20201469T1 (show.php) |
| HU (1) | HUE050664T2 (show.php) |
| LT (1) | LT3204359T (show.php) |
| PL (1) | PL3204359T3 (show.php) |
| PT (1) | PT3204359T (show.php) |
| RS (1) | RS60933B1 (show.php) |
| SI (1) | SI3204359T1 (show.php) |
| WO (1) | WO2016055479A1 (show.php) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43677A (fr) * | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| EA036137B1 (ru) * | 2016-04-13 | 2020-10-02 | Юсб Байофарма Спрл | Производные тетрагидроизохинолина |
| CN107698433A (zh) * | 2017-09-12 | 2018-02-16 | 潍坊滨海石油化工有限公司 | 苯乙酸的制备方法 |
| DK3717025T3 (da) * | 2017-12-01 | 2021-11-22 | UCB Biopharma SRL | Billeddannende midler |
| TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| EP3993795A1 (en) * | 2019-07-01 | 2022-05-11 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| WO2021001288A1 (en) * | 2019-07-01 | 2021-01-07 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| JP2023522980A (ja) * | 2020-04-24 | 2023-06-01 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｎｕｒｒ１受容体調節因子及びその使用 |
| CN111943930B (zh) * | 2020-08-25 | 2022-11-01 | 南京三元阳普医药科技有限公司 | Lasmiditan的合成工艺 |
| SI4200280T1 (sl) * | 2020-10-07 | 2024-04-30 | Eli Lilly And Company | Derivati fenil-3,4-dihidroizokvinolin-2(1H)-il-etan-1-ona kot pozitivni alosterični modulatorji dopamin D1 receptorja |
| CA3198635A1 (en) * | 2020-12-03 | 2022-06-09 | UCB Biopharma SRL | Octahydroisoquinolinyl derivatives |
| KR20230121867A (ko) * | 2020-12-18 | 2023-08-21 | 유씨비 바이오파마 에스알엘 | 무정형 고체 분산체 |
| CN116601161A (zh) * | 2020-12-18 | 2023-08-15 | Ucb生物制药有限责任公司 | 2-(3,5-二氯-1-甲基-吲唑-4-基)-1-[(1s,3r)-3-(羟基甲基)-5-(1-羟基-1-甲基-乙基)-1-甲基-3,4-二氢-1h-异喹啉-2-基]乙酮的前药 |
| WO2022129303A1 (en) | 2020-12-18 | 2022-06-23 | UCB Biopharma SRL | Dihydroisoquinolinyl derivatives |
| CA3202993A1 (en) | 2020-12-18 | 2022-06-23 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| US20240299375A1 (en) | 2021-03-08 | 2024-09-12 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis |
| KR20230154968A (ko) | 2021-03-09 | 2023-11-09 | 일라이 릴리 앤드 캄파니 | 파킨슨병 진행을 늦추기 위한 메비달렌 및 다른 d1 양성 알로스테릭 조절제의 용도 |
| CN114671810B (zh) * | 2022-03-21 | 2024-03-22 | 济南鸿湾生物技术有限公司 | 一种咪唑苯脲的制备方法 |
| CN115611768B (zh) * | 2022-11-14 | 2024-03-05 | 郑州大学 | 一种3,4-二氯苯腈的合成方法 |
| CN118724764B (zh) * | 2024-06-07 | 2025-11-18 | 绍兴文理学院 | 一种芳基伯磺酰胺类化合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766131A (en) * | 1980-10-17 | 1988-08-23 | Pennwalt Corporation | 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics |
| MXPA04005988A (es) | 2001-12-19 | 2004-09-27 | Lundbeck & Co As H | 3,4-dihidro-1h-isoquinolin-2-il-derivados. |
| EP1749001B1 (en) * | 2004-04-29 | 2010-03-03 | Aventis Pharmaceuticals, Inc. | 3-piperidinylisochroman-5-ols as dopamine agonists |
| BRPI0808525A2 (pt) * | 2007-03-01 | 2014-08-19 | Janssen Pharmaceutica Nv | Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3 |
-
2015
- 2015-10-06 RS RS20201139A patent/RS60933B1/sr unknown
- 2015-10-06 ES ES15775688T patent/ES2821821T3/es active Active
- 2015-10-06 JP JP2017518989A patent/JP6622299B2/ja active Active
- 2015-10-06 CA CA2963951A patent/CA2963951C/en active Active
- 2015-10-06 CN CN201580064005.3A patent/CN107001278B/zh not_active Expired - Fee Related
- 2015-10-06 EP EP15775688.3A patent/EP3204359B1/en active Active
- 2015-10-06 PT PT157756883T patent/PT3204359T/pt unknown
- 2015-10-06 EA EA201790785A patent/EA035544B1/ru not_active IP Right Cessation
- 2015-10-06 WO PCT/EP2015/073053 patent/WO2016055479A1/en not_active Ceased
- 2015-10-06 SI SI201531348T patent/SI3204359T1/sl unknown
- 2015-10-06 US US15/517,795 patent/US10105359B2/en active Active
- 2015-10-06 LT LTEP15775688.3T patent/LT3204359T/lt unknown
- 2015-10-06 PL PL15775688.3T patent/PL3204359T3/pl unknown
- 2015-10-06 HU HUE15775688A patent/HUE050664T2/hu unknown
- 2015-10-06 HR HRP20201469TT patent/HRP20201469T1/hr unknown
- 2015-10-06 DK DK15775688.3T patent/DK3204359T3/da active
- 2015-10-06 BR BR112017007123-1A patent/BR112017007123B1/pt not_active IP Right Cessation
-
2020
- 2020-09-30 CY CY20201100923T patent/CY1123417T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2963951C (en) | 2023-02-28 |
| WO2016055479A1 (en) | 2016-04-14 |
| CN107001278B (zh) | 2020-11-24 |
| US10105359B2 (en) | 2018-10-23 |
| HUE050664T2 (hu) | 2020-12-28 |
| US20170304292A1 (en) | 2017-10-26 |
| EA201790785A1 (ru) | 2017-10-31 |
| DK3204359T3 (da) | 2020-09-14 |
| PL3204359T3 (pl) | 2021-03-22 |
| ES2821821T3 (es) | 2021-04-27 |
| EP3204359A1 (en) | 2017-08-16 |
| JP2017530185A (ja) | 2017-10-12 |
| BR112017007123B1 (pt) | 2023-01-31 |
| HRP20201469T1 (hr) | 2020-12-11 |
| PT3204359T (pt) | 2020-09-24 |
| SI3204359T1 (sl) | 2020-10-30 |
| EA035544B1 (ru) | 2020-07-03 |
| EP3204359B1 (en) | 2020-07-01 |
| BR112017007123A2 (pt) | 2017-12-19 |
| CA2963951A1 (en) | 2016-04-14 |
| RS60933B1 (sr) | 2020-11-30 |
| CN107001278A (zh) | 2017-08-01 |
| CY1123417T1 (el) | 2021-12-31 |
| LT3204359T (lt) | 2020-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6622299B2 (ja) | テトラヒドロイソキノリン誘導体 | |
| CN113214287B (zh) | Hpk1抑制剂及其使用方法 | |
| JP6925435B2 (ja) | ピリミジニル−ピリジルオキシ−ナフチル化合物及びｉｒｅ１関連疾患及び障害を治療する方法 | |
| JP6211530B2 (ja) | 含窒素複素環化合物 | |
| JP6505023B2 (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| TW202229240A (zh) | 新穎化合物 | |
| EA021126B1 (ru) | Замещенные изохинолиноны и хинализолиноны | |
| KR20170063599A (ko) | NR2B의 N-알킬아릴-5-옥시아릴-옥타히드로-시클로펜타[c]피롤 음성 알로스테릭 조정제 | |
| US11345666B2 (en) | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | |
| EP3204374B1 (en) | Isoindoline derivatives | |
| EP4038052A2 (en) | Prostaglandin e2 (pge2) ep4 receptor antagonists | |
| TW202134213A (zh) | 具有水解磷脂酸受體作動活性之化合物及其醫藥用途 | |
| WO2023183437A1 (en) | Tead inhibitors and methods of use | |
| HK40057478B (zh) | Hpk1抑制剂及其使用方法 | |
| TW201341380A (zh) | 磺醯胺衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181005 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181005 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190524 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190523 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20190823 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191119 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191121 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6622299 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |